3.135

3.47% 0.105

Aclaris Therapeutics Inc (ACRS)

Overview News Price History Option Chain Financials Why ACRS Down? Discussions Forecast

Aclaris Therapeutics Inc stock is traded at $3.135, with a volume of 255.76K. It is up +3.47% in the last 24 hours and up +25.90% over the past month. Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Previous Close:

$3.03

Open:

$3.03

24h Volume:

255.76K

Relative Volume:

0.21

Market Cap:

$339.66M

Revenue:

$27.08M

Net Income/Loss:

$-37.00M

P/E Ratio:

-6.0288

EPS:

-0.52

Net Cash Flow:

$-18.46M

1W Performance:

-6.70%

1M Performance:

+25.90%

6M Performance:

+120.77%

1Y Performance:

+1.79%

1-Day Range:

$3.03

$3.135

1-Week Range:

$3.03

$3.4117

52-Week Range:

$1.05

$3.475

Aclaris Therapeutics Inc Stock (ACRS) Company Profile

Name

Aclaris Therapeutics Inc

Sector

Healthcare (1136)

Industry

Biotechnology (632)

Phone

484-324-7933

Address

701 LEE ROAD, WAYNE, PA

Employee

Twitter

@aclaristx

Next Earnings Date

2025-02-24

Latest SEC Filings

ACRS's Discussions on Twitter

Compare ACRS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACRS Aclaris Therapeutics Inc	3.135	328.29M	27.08M	-37.00M	-18.46M	-0.52
VRTX Vertex Pharmaceuticals Inc	446.30	114.05B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	746.37	78.80B	14.25B	4.58B	3.88B	41.77
ALNY Alnylam Pharmaceuticals Inc	400.00	51.80B	3.21B	43.57M	221.36M	0.2405
ARGX Argen X Se Adr	850.97	53.08B	3.06B	1.28B	447.35M	19.67
INSM Insmed Inc	168.14	42.33B	447.02M	-1.18B	-906.14M	-6.1812

Aclaris Therapeutics Inc Stock (ACRS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jul-10-25	Resumed	Piper Sandler	Overweight
May-28-25	Initiated	Wedbush	Outperform
Mar-18-25	Resumed	Cantor Fitzgerald	Overweight
Dec-23-24	Upgrade	H.C. Wainwright	Neutral → Buy
Nov-20-24	Upgrade	Cantor Fitzgerald	Neutral → Overweight
Nov-19-24	Upgrade	BTIG Research	Neutral → Buy
Nov-19-24	Upgrade	Jefferies	Hold → Buy
Nov-19-24	Upgrade	Leerink Partners	Market Perform → Outperform
Nov-18-24	Upgrade	Piper Sandler	Neutral → Overweight
Jan-22-24	Downgrade	H.C. Wainwright	Buy → Neutral
Nov-13-23	Downgrade	William Blair	Outperform → Mkt Perform
Oct-03-23	Initiated	Evercore ISI	Outperform
Dec-14-22	Initiated	Stifel	Buy
Dec-01-22	Initiated	Goldman	Buy
Oct-06-22	Initiated	BTIG Research	Buy
Jul-23-21	Resumed	Jefferies	Buy
Jun-15-21	Initiated	Piper Sandler	Overweight
Apr-21-21	Initiated	H.C. Wainwright	Buy
Oct-22-19	Upgrade	SVB Leerink	Mkt Perform → Outperform
Sep-06-19	Downgrade	JMP Securities	Mkt Outperform → Mkt Perform
Jun-27-19	Downgrade	SVB Leerink	Outperform → Mkt Perform
May-06-19	Initiated	SVB Leerink	Outperform
Mar-28-18	Resumed	Leerink Partners	Outperform
Feb-09-18	Initiated	Guggenheim	Buy
Jun-16-17	Initiated	Cantor Fitzgerald	Overweight
Nov-29-16	Initiated	Leerink Partners	Outperform
Sep-30-16	Initiated	JMP Securities	Mkt Outperform
Jun-10-16	Initiated	Guggenheim	Buy
Nov-02-15	Initiated	Citigroup	Buy
Nov-02-15	Initiated	Jefferies	Buy

View All

Aclaris Therapeutics Inc Stock (ACRS) Latest News

03:36 AM

Why Aclaris Therapeutics Inc. stock could see breakout soon2025 Sector Review & Free Reliable Trade Execution Plans - Улправда

03:36 AM

Dec 17, 2025

Why Aclaris Therapeutics Inc. stock remains undervaluedWeekly Trading Summary & Real-Time Buy Zone Alerts - Bollywood Helpline

Dec 17, 2025

Can Upcoming ATI-2138 And Bosakitug Data Drive Momentum For Aclaris Therapeutics In 2026? - RTTNews

Dec 17, 2025

Dec 15, 2025

Aclaris Therapeutics Earnings Notes - Trefis

Dec 15, 2025

Dec 08, 2025

Aclaris Therapeutics Stock Jump Looks Great, But How Secure Is That Gain? - Trefis

Dec 08, 2025

It is Poised to be a Bull Market for Aclaris Therapeutics Inc (ACRS) - setenews.com

Dec 08, 2025

Dec 05, 2025

Can Aclaris Therapeutics Inc. stock deliver sustainable ROE2025 Key Highlights & Consistent Return Investment Signals - Newser

Dec 05, 2025

Dec 04, 2025

Why Aclaris Therapeutics Inc. (8AT) stock is a must watch tickerTrade Risk Assessment & Weekly Stock Performance Updates - Newser

Dec 04, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of "Moderate Buy" by Brokerages - MarketBeat

Dec 04, 2025

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Given Consensus Recommendation of “Moderate Buy” by Brokerages - Defense World

Dec 04, 2025

How Aclaris Therapeutics Inc. (8AT) stock correlates with oil markets2025 Growth vs Value & Technical Pattern Recognition Alerts - Newser

Dec 04, 2025

Can Comfort Intech Limited Maintain Profitability in a Rising Rate EnvironmentCandlestick Trading Patterns & Free Dynamic Profit Opportunities - earlytimes.in

Dec 04, 2025

Dec 03, 2025

Is Aclaris Therapeutics Inc. stock attractive for income investors2025 Big Picture & Safe Capital Growth Trade Ideas - Newser

Dec 03, 2025

Dec 02, 2025

Aclaris Therapeutics (ACRS) Stock Analysis Report | Ratings, Financials & Performance - Benzinga

Dec 02, 2025

Aclaris Therapeutics engages investors at Piper Sandler Conference - Traders Union

Dec 02, 2025

Dec 01, 2025